H. Lundbeck company profile

HLUN.A · Nasdaq Copenhagen · DKK

Compare H. Lundbeck
kr 57.80Change from previous close: −1.03%Absolute change: −kr 0.60

Close · November 17, 2026

Company profile

H. Lundbeck has 5,000 employees and is headquartered in Valby, Denmark.

Patients with psychiatric and neurological disorders in Europe, the United States and other international markets are served by H. Lundbeck A/S, which researches, develops, manufactures and commercializes pharmaceuticals for these conditions, including schizophrenia, bipolar I disorder, depression, migraine, epilepsy, dementia and Parkinson's disease. Its products include Abilify Maintena, Brintellix, Rexulti, Vyepti and Azilect. Its pipeline includes Eptinezumab in phase 3 testing for cluster headache and bexicaserin in phase 3 for developmental and epileptic encephalopathies. A strategic research collaboration with Contera Pharma targets oligonucleotide-based medicines for serious neurological conditions. The company was founded in 1915.

In the fiscal year ended December 2025, revenue reached DKK 24.6 billion, up 11.9% from the previous year, and net profit came to DKK 3.2 billion. The company employs 5,000 people and is headquartered in Valby, Denmark.

Company facts

Industry
Drug Manufacturers - Specialty & Generic
Country
Denmark
Headquarters
Ottiliavej 9, 2500, Valby
Employees
5,000
Listing
HLUN.A · Nasdaq Copenhagen
Currency
DKK
ISIN
DK0061804697

H. Lundbeck and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
H. LundbeckHLUN.ADenmark$8.49B5,00024.4%14.2
IpsenIPNFrance$14.2B5,53527.4%25.5
Swedish Orphan BiovitrumSOBISweden$16.27B2,20730.9%25.0
Laboratorios Farmaceuticos RoviROVISpain$3.93B1,95020.2%17.4
Siegfried HoldingSFZNSwitzerland$3.53B4,45416.7%17.3
AlmirallALMSpain$2.53B2,1089.6%32.1

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare H. Lundbeck with its competitors